|
|
Comparison effect of Alogliptin and Acarbose in the treatment of newly diagnosed type 2 diabetes mellitus and their effects on gastrointestinal related hormones |
XU Rong XIA Wen-yan GUO LiZENG Shu-qin LYU Wei-ming▲ |
Department of Endocrine,the First Affiliated Hospital of Gannan Medical College,Jiangxi Province,Ganzhou 341000,China |
|
|
Abstract Objective To investigate the clinical effects of Alogliptin and Acarbose on newly diagnosed type 2 diabetes mellitus(7%<HbA1c<8.5%)and their effects on gastrointestinal hormones.Methods Sixty newly diagnosed type 2 diabetes mellitus patients in the Department of endocrinology of our hospital from January 2017 to January 2018 were selected,they were divided into treatment group and control group according to random number table method,with 30 cases in each group.The patients in the treatment group were treated with Alogliptin and the patients in the control group were treated with Acarbose for 24 weeks.Blood sugar,HbA1c and body mass index(BMI)were compared between the two groups before and after treatment,changes of gastrointestinal hormones and occurrence of adverse reactions.Results The levels of fasting blood glucose(FPG),postprandial 2-hour blood glucose(2-hour PG)and HbA1c in the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).BMI level of the two groups after treatment was lower than that before treatment,but there was no significant difference(P>0.05).There was no significant difference in FPG,2 h PG and HbA1c between the two groups(P>0.05).Gastrin and gastrin levels in the treatment group after treatment were lower than those before treatment on fasting and 2 hours after meal(P<0.05).In the control group after treatment,the level of ghrelin in fasting and 2 hours after meal was lower than that before treatment,and the level of ghrelin in fasting and 2 hours after meal was higher than that before treatment,but there was no significant difference(P>0.05).The levels of ghrelin and gastrin in the treat-ment group after treatment were lower than those in the control group on fasting and 2 hours after meal(P<0.05).There were no severe gastrointestinal adverse reactions and severe hypoglycemia in both groups.Conclusion Both Alogliptin and Acarbose significantly improved blood sugar in newly diagnosed type 2 diabetes mellitus(7%<HbA1c<8.5%),however,the effect of agritin on reducing fasting and postprandial gastrin is more significant,and it can be used as an effective clinical treatment for type 2 diabetes mellitus.
|
|
|
|
|
[1] |
李维辉,苟佳佳,李靖柯.抗糖尿病药物dpp-4抑制剂的临床应用进展[J].重庆医学,2016,45(19):2706-2708.
|
[2] |
陈文文,党和勤,耿涛,等.新型降糖药dpp-4抑制剂研究进展[J].中国医院药学杂志,2016,36(6):511-517.
|
[3] |
曹红斌.阿格列汀联合二甲双胍治疗新诊断2型糖尿病患者的效果与安全性[J].中国当代医药,2018,25(26):69-71.
|
[4] |
段小云,冯碧敏,张成斌,等.阿格列汀与其他口服降糖药比较治疗2型糖尿病的系统评价[J].中国新药与临床杂志,2017,36(4):226-233.
|
[5] |
z1,K1y1c1 S,Ersoy C,et al.Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes[J].Diabetes Res Clin Pract,2011,94(2):212-216.
|
[6] |
吴珂.西格列汀与阿卡波糖对初发2型糖尿病的疗效比较和胃肠道相关激素的影响研究[J].2014,20(36):134-135.
|
[7] |
李庆玲.西格列汀与阿卡波糖对初发2型糖尿病的疗效比较和胃肠道相关激素的影响研究[J].糖尿病新世界,2014,34(21):3-4,6.
|
[8] |
叶潇.西格列汀与阿卡波糖对初发型糖尿病的疗效比较和胃肠道相关激素的影响研究[D].广州:南方医科大学,2012.
|
[9] |
谢树英,张凌,张秋平.“血糖管理三人行”项目对糖尿病患者血糖控制及胰岛素注射技术的影响[J].中国当代医药,2018,25(24):182-184.
|
[10] |
卢乐,毛皓愉,孙霞.25-羟维生素D3与2型糖尿病患者下肢动脉粥样硬化病变的相关性研究[J].中国现代医生,2018,56(17):38-41.
|
[11] |
廖安辉.奥美拉唑联合云南白药对儿童急性胃炎炎症因子及胃泌素水平的影响[J].海南师范大学学报(医学版),2018,15(4):181-184.
|
[12] |
洪世华,吴菊琴,柯瑞琼,等.甘精胰岛素联合格列美脲对比联合吡格列酮治疗新诊断2型糖尿病的疗效观察[J].中国糖尿病杂志,2014,22(12):113-115.
|
[13] |
中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科学杂志,2018,38(4):292-344.
|
[14] |
刘瑛.dpp-4抑制剂治疗2型糖尿的系统评价[D].昆明:昆明医科大学,2016.
|
[16] |
顾丹阳.胃饥饿素与2型糖尿病患者胰岛素抵抗及胰岛功能的相关性研究[D].南京:南京医科大学,2018.
|
[17] |
张雪梅,印娟,李庭赞,等.胃蛋白酶原及胃泌素-17检测在胃肠疾病诊断中的作用[J].山西医药杂志,2018,47(18):2217-2218.
|
[15] |
Barzilai N,Guo H,Mahoney EM,et al.Efficacy and tolerability of sitagliptin monotherapy in elderly diabetes patients with type 2 diabetes:a randomized,double-blind,placebocontrolled trial[J].Curr Med Res Opin,2011,27(5):1049-1058.
|
[18] |
Ukkola O.Ghrelin and metabolic disorders[J].Curr Protein Pept Sci,2009,10(1):2-7.
|
|
|
|